New Gene-Editing Candidates Target Blood Disorders, as Gene Therapies Start to Hit the Market

Please subscribe and tell your friends why it’s worthwhile. Quality journalism costs money. When you subscribe to Timmerman Report at $149 per year, you reward quality independent biotech reporting, and encourage more.


You may also like

Early Cancer Screening is Maturing. What Will It Mean for Drug Developers?
Autoimmunity Research Paves the Way for New Ideas in Halting, Preventing Type 1 Diabetes
As CAR-T Ranks Expand, Industry Scrambles to Solve Long-Standing Manufacturing Challenges
CRISPR Boosts Animal Models, Making Preclinical Research More Efficient